Dimensional Fund Advisors LP Has $155.75 Million Position in Hologic, Inc. $HOLX

Key Points

• Dimensional Fund Advisors trimmed its Hologic stake by 8.4% in Q3, selling 211,923 shares and now holds 2,307,833 shares worth about $155.75 million (≈1.04% of the company).
• Analysts mostly rate HOLX a "Hold" (13 Holds, 2 Buys) with an average target price of $78.42, amid several recent downgrades and modest target revisions.
• Recent quarter: Hologic missed estimates with EPS $1.04 vs. $1.09 expected and revenue $1.05B vs. $1.07B, while the stock trades near its 1‑year high (~$75.59) and the company has a market cap of about $16.9B (P/E ~31.5).

Dimensional Fund Advisors LP cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 8.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,307,833 shares of the medical equipment provider's stock after selling 211,923 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.04% of Hologic worth $155,749,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Winnow Wealth LLC bought a new stake in Hologic during the third quarter worth about $26,000. Root Financial Partners LLC bought a new position in Hologic in the third quarter valued at approximately $27,000. SJS Investment Consulting Inc. grew its stake in Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider's stock valued at $32,000 after purchasing an additional 362 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in shares of Hologic during the 2nd quarter worth approximately $33,000. Finally, Smartleaf Asset Management LLC increased its position in shares of Hologic by 168.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 494 shares of the medical equipment provider's stock worth $33,000 after purchasing an additional 310 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on HOLX shares. Morgan Stanley increased their price objective on Hologic from $69.00 to $76.00 and gave the company an "equal weight" rating in a report on Tuesday, November 11th. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, January 12th. BNP Paribas Exane cut shares of Hologic from a "strong-buy" rating to a "hold" rating and set a $79.00 price target for the company. in a research note on Friday, November 21st. Weiss Ratings reissued a "hold (c)" rating on shares of Hologic in a research report on Wednesday, January 28th. Finally, Evercore cut shares of Hologic from an "outperform" rating to an "in-line" rating and dropped their target price for the company from $79.00 to $78.00 in a report on Monday, January 5th. Two investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $78.42.

Hologic Stock Down 0.2%

HOLX opened at $75.59 on Tuesday. The stock's fifty day simple moving average is $75.06 and its 200 day simple moving average is $72.49. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $75.75. The stock has a market cap of $16.87 billion, a PE ratio of 31.50, a price-to-earnings-growth ratio of 2.25 and a beta of 0.73. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.09 by ($0.05). The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.87 EPS. As a group, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc NASDAQ: HOLX is a global medical technology company specializing in women's health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.